FDA Issues Complete Response Letter to Alimera Sciences Regarding New Drug Application for ILUVIEN(R)
ATLANTA -- Alimera Sciences, Inc. , a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it received a Complete Response Letter from the U.S.

FDA Cracks Down on Illegal Supplements
The Food and Drug Administration is cracking down on manufacturers of certain weight loss, body building and sexual enhancement supplements that contain potentially dangerous ingredients